Gird your kidneys? A novel approach to ADPKD therapeutics

Andrew Mallett^{1

2

3

4}

Affiliations

¹ Department of Renal Medicine, Townsville University Hospital, Douglas, QLD, 4029, Australia. Andrew.mallett@health.qld.gov.au.
² College of Medicine and Dentistry, James Cook University, Douglas, QLD, Australia. Andrew.mallett@health.qld.gov.au.
³ Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia. Andrew.mallett@health.qld.gov.au.
⁴ Faculty of Medicine, The University of Queensland, Herston, QLD, Australia. Andrew.mallett@health.qld.gov.au.

Comment

Andrew Mallett. J Nephrol. 2023 Apr.

. 2023 Apr;36(3):933-934.

doi: 10.1007/s40620-022-01425-7. Epub 2022 Aug 12.

Andrew Mallett^{1

2

3

4}

¹ Department of Renal Medicine, Townsville University Hospital, Douglas, QLD, 4029, Australia. Andrew.mallett@health.qld.gov.au.
² College of Medicine and Dentistry, James Cook University, Douglas, QLD, Australia. Andrew.mallett@health.qld.gov.au.
³ Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia. Andrew.mallett@health.qld.gov.au.
⁴ Faculty of Medicine, The University of Queensland, Herston, QLD, Australia. Andrew.mallett@health.qld.gov.au.

No abstract available

Comment on

Novel 3D capsule device to restrict kidney volume expansion on polycystic kidney progression: feasibility study in a rat model.
Bae KT, Kumamoto K, Yoshimura A, Kugita M, Horie S, Yamaguchi T, Bae JT, Nagao S. Bae KT, et al. J Nephrol. 2022 Apr;35(3):1033-1040. doi: 10.1007/s40620-021-01160-5. Epub 2021 Nov 10. J Nephrol. 2022. PMID: 34757576

1. Cornec-Le Gall E, Alam A, Perrone RD (2019) Autosomal dominant polycystic kidney disease. Lancet 393(10174):919–935 - DOI - PubMed
1. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407–2418 - DOI - PubMed - PMC
1. Capuano I, Buonanno P, Riccio E, Amicone M, Pisani A (2022) Therapeutic advances in ADPKD: the future awaits. J Nephrol 35(2):397–415 - DOI - PubMed
1. Bae KT, Kumamoto K, Yoshimura A, Kugita M, Horie S, Yamaguchi T, Bae JT, Nagao S (2022) Novel 3D capsule device to restrict kidney volume expansion on polycystic kidney progression: feasibility study in a rat model. J Nephrol 35(3):1033–1040 - DOI - PubMed
1. Chebib FT, Torres VE (2021) Assessing Risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy. Am J Kidney Dis 78(2):282–292 - DOI - PubMed